E-Prescribing Vendors Talk Back


By Neil Versel, contributing editor

November 4, 2008 | A month ago, acting Centers for Medicare and Medicaid Services (CMS) administrator Kerry Weems said that physicians can no longer use cost as an excuse for not switching to electronic prescribing. “The business case is turned around,” Weems said citing the affordability of the technology and reasonably small workflow changes it requires.

If the vendor booths at the recent Medical Group Management Association (MGMA) annual meeting were any indication, the promise of 2 percent Medicare bonuses for e-prescribing has captured the attention of doctors and spurred all kinds of interest in health-IT.

“It’s created a sense of urgency that hasn’t been there before,” says Greg White, executive director of health care banking and payer solutions for RelayHealth, a McKesson subsidiary that offers e-prescribing software and services.

Doug Hart, RelayHealth’s senior director of marketing, says e-prescribing gives medical practices more of an advantage than before because it can produce a much faster return on investment than a full electronic medical record, something that is particularly important in this tough economy. Hart reports “lots of interest” in the company’s offering specifically because of the Medicare incentives, but also is seeing inquiries about secure messaging with patients, automation of referrals, appointment scheduling, and the population of personal health records through the RelayHealth user portal.

Starting Jan. 1, physicians can earn an extra 2 percent on top of regular Medicare Part B fees for “successful” e-prescribing. (CMS promises a definition of “successful” as well as detailed rules for the program by Nov. 15.) The bonus falls to 1 percent in 2011, then 0.5 percent in 2013. Meanwhile, those who have not made the switch by 2012 will be subject to penalties. (See “CMS Focuses on E-Prescribing.”)

Since Congress authorized the bonuses with the passage of the Medicare Improvements for Patients and Providers Act in mid-July, Allscripts-Misys Healthcare Solutions, the product of the recently completed merger of ambulatory systems vendors Allscripts Healthcare Solutions and Misys Healthcare Systems, has seen 15 percent monthly growth in the number of e-prescribing customers.

Even though Allscripts offers a free, standalone e-prescribing system through its National ePrescribing Patient Safety Initiative, the Chicago-based company had a lot of interest in complete EMRs from MGMA attendees who saw e-prescribing demos. “It leads to questions about what’s the pathway from e-prescribing to a full EMR,” says Allscripts president and chief operating officer Lee Shapiro.

Similarly, Sage Software Healthcare spokeswoman Lynne Durham says e-prescribing came up in the first 10 conversations she had at the meeting, though much of the interest was in e-prescribing as part of a broader EMR. Sage customers are writing more than 700,000 electronic prescriptions a month, and the majority are from users of the full EMR, Durham reports. “We haven’t seen a lot of rush for the standalone product,” she says.

Eclipsys, a hospital systems vendor that acquired ambulatory IT company MediNotes in October, has had a similar experience. “We’re seeing less interest in standalone e-prescribing than perhaps the buzz was six months ago,” says Thomas R. Cooke, Eclipsys senior vice president of business development.

Click here to log in.

0 Comments

Add Comment

Text Only 2000 character limit

Page 1 of 1

White Papers & Special Reports

thomson reuters image
Biomarkers: An Indispensible Addition to the Drug Development Toolkit
Examining the Potential of Biomarkers
Sponsored by Thomson Reuters

Biomarkers are becoming an essential part of clinical development. In this white paper, Thomson Reuters provides insight from experts in industry and academia, and explores the role of biomarkers as evaluative tools in improving clinical research and the challenges this presents.

Discover the potential of biomarkers to:

  • Improve decision making
  • Accelerate drug development
  • Reduce development costs


BlueArc_Scientific Data
Scientific Data Lifecycle Management: Preparing for Storage in an Uncertain Future
Sponsored by BlueArc

Managing vast and overwhelming streams of gene sequencing data today requires ultra-high performance systems and processes. With continued rapid advancement and improvements in gene sequencing, expect tomorrow’s instruments to output quantities of genomic information that will dwarf current levels. Help your organization maintain data control and prepare for the future of sequencing through this informative paper that discusses:

  • The information technology challenges of gene sequencing
  • “Intelligent” methods for data management and customization
  • System survival tips... Deciding what data to keep or delete
  • New tools to keep scientists ahead of impending data torrents


SAS Managed image
Managed Innovation, Assured Compliance
Developing, executing and managing the transformation, analysis and submission of clinical research data with SAS® Drug Development
Sponsored by SAS
Get better products to market faster. Download this white paper to discover the top ten challenges facing life science executives and how to overcome them. See how SAS Drug Development transforms clinical data into true innovation.


Life Science Webcasts & Podcasts

Presented by Trade Commission of Spain

Spain Biotech: An Engine for Economic Change 

TCS podcastDiscover how Spain is focusing on biotechnology to be an engine for economic change through gradual internationalization, development and technology transfer.

Regional governments are actively investing in public and private biology research and promoting the creation of knowledge-based companies. Spain’s human capital combined with aggressive investment in biotech research and infrastructure has led to the creation of bio-clusters.

Today, there are nearly 700 Spanish companies engaged in biotechnology, with almost 50 percent growth in funding devoted to research. In fact, spending on internal R & D in biotechnology has grown 46 percent and is close to 300 million Euros.

Access the podcast 

 



More Podcasts

Job Openings

saic_logo

MANAGER, SCIENTIFIC COMPUTING & PROGRAMMING
(Bioinformatics Manager)
SAIC-Frederick, Inc has an exciting opportunity for a Manager, Scientific Computing & Programming - Core Genoytyping Facility in Gaithersburg, Maryland.  In this role, you will lead the Bioinformatics & Analysis Group.
Master’s or equivalent required.  PhD preferred. Six years experience in development of scientific programs in high-performance computing environment including five years supporting scientific research in computational chemistry, biology, or genetics, & two years supervisory experience.  View complete job posting & apply: www.saic-frederick.com. Position #146945.

For reprints and/or copyright permission, please contact The YGS Group, 1808 Colonial Village Lane, Lancaster, PA;

(717) 399-1900 ext. 125, or via email to Ashley.Zander@theYGSgroup.com.